Cancer reports最新文献

{"title":"Clinical Profile of Pediatric Solid Tumors: Experience From a Tertiary Care Center in Ethiopia","authors":"Mamude Dinkiye,&nbsp;Deme Abdissa,&nbsp;Tadele Hailu,&nbsp;Aziza T. Shad,&nbsp;Yoram Unguru","doi":"10.1002/cnr2.70222","DOIUrl":"https://doi.org/10.1002/cnr2.70222","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pediatric solid tumors are a significant health challenge worldwide, especially in low- and middle-income countries such as Ethiopia, where healthcare infrastructure is limited and treatment modalities are scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aims to understand the epidemiological characteristics of these tumors and short-term treatment outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>A retrospective study spanning a period of 2 years and 8 months was conducted among all children below age 15 years admitted to St. Paul's Hospital Millennium Medical College hemato-oncology unit with a pediatric solid tumor. Data from patient charts was extrapolated and analyzed using SPSS version 29. A total of 173 pediatric solid tumor patients were identified over the study period. 22.6% of patients were treated in the first year, 34.6% of patients were treated in the second year, and 42.8% of patients were treated in the last 8 months of the study period. 56.1% of them were males. Most patients came from the Oromia region. The most frequent solid tumors were retinoblastoma, Wilms tumor, and rhabdomyosarcoma. Eighty-six patients are still on treatment, 23 patients achieved complete remission, 4 relapsed, 2 were defaulters, 5 patients were lost to follow-up, 21 died, 5 were referred to other hospitals, and 10 opted against treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study reveals a rising trend in childhood solid tumor cases over the years. A significant proportion of patients achieved remission, whereas most remain under treatment or follow-up care. A relatively small percentage experienced relapses, with some cases of defaulters, loss to follow-up, and a few instances of mortality. Implementing early detection strategies and community-based awareness programs could improve outcomes by encouraging timely diagnosis and intervention.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70222","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143926060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Malignant Melanoma on the Tongue: A Case Report and Review of the Literature","authors":"Maziar Motiee-Langroudi,&nbsp;Athena Farahzadi,&nbsp;Pouyan Aminshakib","doi":"10.1002/cnr2.70215","DOIUrl":"https://doi.org/10.1002/cnr2.70215","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Melanoma of the oral mucosa is an uncommon cancer arising from the tissues lining the mouth. Among oronasal malignant melanomas, tongue melanoma makes up a mere 2%. Optimal treatments for this rare and often late-stage disease remain elusive. However, surgery with free margins is considered the primary treatment and is often combined with other therapies such as neck dissection, adjuvant radiotherapy, chemotherapy, and immunotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>This case involves a 33-year-old woman with a history of malignant melanoma on her tongue. She had previously undergone a partial glossectomy and was on maintenance imatinib treatment for ~2 years. During her follow-up, a new lesion was discovered on her tongue, which was confirmed to be malignant melanoma and was resected. The tumor exhibited a depth of invasion of 8 mm. All surgical margins were clear, with the closest margin being 3 mm. The lesion was reconstructed with a submental flap. Adjuvant radiotherapy was also given. The patient has been on maintenance follow-up for 3 years with no signs of recurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Malignant melanoma should be considered in the differential diagnosis of pigmented and non-pigmented lesions of the tongue and oral mucosa. A thorough clinical evaluation, followed by histopathological and immunohistochemical examination of any suspicious lesions, is essential for early diagnosis. Early detection and prompt treatment are crucial for optimizing patient outcomes and improving survival rates.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Frequency Mutations in TP53, AXIN1, CTNNB1, and KRAS, and Polymorphisms in JAK1 Genes Among Mongolian HCC Patients","authors":"Nomin Bold,&nbsp;Khurelsukh Buyanbat,&nbsp;Ariya Enkhtuya,&nbsp;Nomin Myagmar,&nbsp;Gerelsuren Batbayar,&nbsp;Zolzaya Sandag,&nbsp;Dolgion Damdinbazar,&nbsp;Nomuun Oyunbat,&nbsp;Tuul Boldbaatar,&nbsp;Ankhbayar Enkhbaatar,&nbsp;Gan-Erdene Baatarjav,&nbsp;Taivan Nanzaddorj,&nbsp;Tsendsuren Oyunsuren,&nbsp;Gantulga Davaakhuu","doi":"10.1002/cnr2.70227","DOIUrl":"https://doi.org/10.1002/cnr2.70227","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mongolia has the highest incidence of liver cancer worldwide, largely driven by a high prevalence of hepatitis virus infections. Mutations in oncogenes and tumor suppressor genes provide valuable insights into the molecular mechanisms of hepatocellular carcinoma (HCC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to investigate the prevalence of mutations in key oncogenes and tumor suppressor genes in Mongolian HCC patients and to explore their molecular mechanisms, particularly in relation to hepatitis virus infections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>We analyzed 55 tumor tissue samples from Mongolian HCC patients (2019–2021), identifying mutations in <i>TP53</i>, <i>CTNNB1</i>, <i>AXIN1</i>, <i>KRAS</i>, and <i>JAK1</i> through sequencing. Western blotting was used to assess β-catenin and p53 protein levels. Our findings showed p53 overexpression in tumors with <i>TP53</i> mutations (F270I and S362S), while mutations such as R213* and a short-sequence deletion upstream of intron 7 produced premature stop codons, resulting in truncated p53 and loss of tumor suppressor function. β-catenin accumulation was observed in tumors with <i>CTNNB1</i> mutations (D32N/Y, S33C/Y, S34V, S37P, T41A, and S45P). <i>CCND1</i> expression, a key target of the Wnt/β-catenin pathway, was significantly upregulated in tumors harboring <i>CTNNB1</i> and <i>AXIN1</i> mutations (<i>p</i> = 0.02213). Statistical analysis revealed a positive correlation between β-catenin and <i>CCND1</i> expression levels (<i>r</i> = 0.42703). Hepatitis virus infections were significantly associated with these mutations (<i>p</i> &lt; 0.01), suggesting a link between viral infection and genetic alterations in HCC development. Compared to TCGA data, our cohort displayed a significantly higher mutation frequency (<i>p</i> &lt; 0.001 and <i>p</i> &lt; 0.05), indicating potential regional genetic and environmental influences.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provides insights into the molecular mechanisms of HCC in Mongolia, highlighting distinct mutational patterns in <i>TP53</i>, <i>CTNNB1</i>, <i>AXIN1</i>, and <i>KRAS</i>. The association between hepatitis virus infections and these mutations underscores their potential oncogenic impact and may inform future therapeutic strategies for HCC in this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70227","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Size Increment During Surveillance in Papillary Thyroid Cancer: Evidence Synthesis and Dose–Response Meta-Analysis","authors":"Mohamed Badie Ahmed,&nbsp;Emad Naem,&nbsp;Harman Saman,&nbsp;Abeer Alsherawi,&nbsp;Asma Syed,&nbsp;Noora Al-Abdulla,&nbsp;Latifa Alkaabi,&nbsp;Mahmoud A. Zirie,&nbsp;Suhail A. Doi","doi":"10.1002/cnr2.70183","DOIUrl":"https://doi.org/10.1002/cnr2.70183","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Differentiated thyroid cancer has become a prevalent malignant tumor, particularly papillary thyroid carcinoma (PTC), constituting over 90% of cases. Most PTC lesions are asymptomatic and remain subclinical throughout life, and active surveillance is now being used to monitor the progression of these lesions and intervene when appropriate. This evidence synthesis aims to assess PTC progression in size over time during active surveillance in terms of PTC tumor size progression to or beyond 3 mm during the surveillance period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A dose–response meta-analysis was conducted using the robust error meta-regression method, using time as the “dose” and cumulative progression (%) was assessed. A comprehensive literature review was done using PubMed/MEDLINE and EMBASE from inception till August 2024.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 21 studies from 7 different countries, including 14 648 participants, were included. Incident progression at 2 years of follow-up was 1%, and this increased linearly to 12% at 20 years of follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>It was concluded that progression over the threshold increases linearly over time at approximately less than 1% per year. Therefore, size progression beyond the threshold occurs in a minority and in less than one eighth of subjects by two decades of follow-up.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70183","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143926031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Immunophenotypic Reversal of Chronic Lymphocytic Leukaemia With High Dose Parenteral Methylcobalamin: A Case Report and Brief Review of Cobalamin in Cancer","authors":"Carmen Wheatley","doi":"10.1002/cnr2.70106","DOIUrl":"https://doi.org/10.1002/cnr2.70106","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Supposed ‘spontaneous’ remissions in chronic lymphocytic leukaemia (CLL) are extremely rare. By the most stringent immunophenotypic criteria, there are only seven cases to date of unexplained, immune system effected cures. A historic review of this phenomenon is presented as context for this eighth case of CLL immunophenotypic reversal.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 59-year-old, molecular biologist, stage I CLL, whose diagnosis and recovery were both thoroughly documented, not content to watch and wait, chose to treat himself, after individual tumour susceptibility testing, with evidence based, biological response modifiers, which initially seemed to keep his CLL stable. This included 1 mg of hydroxocobalamin injected i.m. daily. However, after some years his lymphocytosis began slowly to drift upwards. At that point, he was persuaded to change his injection protocol to methylcobalamin, at 50 mg i.m. a day, a dose whose clinical safety is sufficiently well-established, and a form of cobalamin that the research literature shows has anticancer actions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This change in cobalamin form and dose proved a critical turning point. Complete disappearance of the lymphocytosis also coincided with a severe infection and an even further temporary increase of the parenteral methylcobalamin dose, both catalytic factors. In the 4th and 5th years following this, the patient's repeated immunophenotyping showed no clonal disease present. A brief review of the field of cobalamin in cancer research and treatment is given, with discussion of the various mechanisms by which cobalamins may impact on cancer/CLL. Historic analysis reveals that cyanocobalamin is generally cancer promotional, whereas hydroxocobalamin, methylcobalamin and adenosylcobalamin are cancer protective and cytotoxic. It is hypothesised that the actions of cobalamin in cancer aetiology and oncogenesis/progression are intertwined with those of nitric oxide, which tumours regulate to dupe the immune system to their presence, by causing a functional cobalamin deficiency in the host.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70106","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma","authors":"Hoang Dong Duc,&nbsp;Mai Binh Thanh,&nbsp;Mai Bang Hong,&nbsp;Nguyen Thinh Tien,&nbsp;Nguyen Thai Van,&nbsp;Bui Bieu Quang,&nbsp;Nguyen Chau Dinh,&nbsp;Thai Ky Doan","doi":"10.1002/cnr2.70212","DOIUrl":"https://doi.org/10.1002/cnr2.70212","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Aims</h3>\u0000 \u0000 <p>This study presents a detailed analysis of long-term survival and critical factors influencing the outcomes of hepatocellular carcinoma patients treated with stereotactic body radiotherapy (SBRT) and transarterial chemoembolization (TACE). Our findings provide reassurance about the potential of the combination of TACE and SBRT as an effective treatment strategy for patients with large liver tumors due to HCC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective study was conducted on 42 patients with intermediate-stage hepatocellular carcinoma (HCC) at 108 Military Central Hospital between December 2018 and June 2024. Following a single session of TACE, each patient underwent SBRT 1 month later. The SBRT dose ranged from 27.5 to 48 Gy, delivered in 3–5 fractions. The patient survival analysis was conducted using the Kaplan–Meier method while examining prognostic factors influencing survival, which involved log-rank tests and Cox proportional hazards regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 42 patients (83.3% male), 34 patients (81.0%) had tumors measuring ≥ 5 cm. The median follow-up period was 32.2 months (4.5–65.1 months). The median overall survival (OS) was 32.6 months, with the respective 1-, 3-, and 5-year OS rates reported as 73.8%, 24.5%, and 19.6%. Furthermore, the median progression-free survival (PFS) was 16.6 months, with corresponding 1- and 3-year PFS rates of 71.4% and 19.0%. Factors linked to improved OS and PFS included AFP levels and treatment response based on Modified RECIST criteria. Additionally, multivariate analysis identified patient age, EQD2, and BED10 as significant predictors of better survival outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study provides evidence supporting the effectiveness and safety of combining TACE and SBRT as a treatment strategy for patients with large liver tumors due to HCC, instilling confidence in the future of HCC treatment. Positive prognostic factors included patient age, EQD₂, and BED₁₀.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed Abscopal Response 3 Years After Robotic Stereotactic Body Radiation Therapy for Renal Cell Carcinoma: A Case Report","authors":"Zhe Chen,&nbsp;Toshihiro Suzuki,&nbsp;Zennosuke Mochizuki,&nbsp;Hiroshi Takahashi,&nbsp;Kan Marino,&nbsp;Takafumi Komiyama,&nbsp;Hiroshi Onishi","doi":"10.1002/cnr2.70229","DOIUrl":"https://doi.org/10.1002/cnr2.70229","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Renal cell carcinoma (RCC) is the most common malignant tumor of the kidney in adults, with poor prognosis in advanced or metastatic stages. Although traditionally considered radioresistant, RCC has shown a promising response to stereotactic body radiation therapy (SBRT), which not only offers local tumor control but may also induce an abscopal effect, resulting in regression of distant metastases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 54-year-old male with a history of right RCC underwent radical nephrectomy in 2000, followed by partial nephrectomy for a left kidney recurrence in 2005. In 2011, imaging revealed a second recurrence in the left kidney. In 2013, after declining further surgery, he was treated with SBRT for the recurrent left renal lesion. Follow-up imaging revealed a stable renal mass and a solid right lung nodule. Retrospective analysis of prior imaging suggested the presence of pulmonary metastases concurrent with the renal recurrence. The pulmonary nodule progressively enlarged until November 2016 but then spontaneously regressed by November 2017 without any additional systemic or local interventions, and remained stably reduced in size thereafter. Serial imaging from 2018 showed no evidence of new metastatic disease, and the left renal lesion exhibited partial regression. The pulmonary metastasis remained stable, consistent with the occurrence of an abscopal effect that persisted for 3 years. The patient ultimately passed away in 2024 from unrelated causes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case demonstrates the potential of SBRT to induce a systemic abscopal response in metastatic RCC, with sustained control of pulmonary metastasis over 3 years. The findings suggest that SBRT may play a critical role in managing metastatic RCC, warranting further research into its synergy with immunotherapy for long-term therapeutic benefit.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70229","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143919350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Aamong Ppolymorphisms in the Aapoptosis-Rrelated NKX3-1, Caspase-3, Caspase-9, and BCL-2 Genes and Prostate Cancer Susceptibility From 9706 Cases and 12,567 Controls","authors":"Yanyan Feng,&nbsp;Zhenting Feng,&nbsp;Dan Li,&nbsp;Jiandong Gui,&nbsp;Zhihong Song,&nbsp;Xiaohua Xie,&nbsp;Lijie Zhu,&nbsp;Yuanyuan Mi","doi":"10.1002/cnr2.70206","DOIUrl":"https://doi.org/10.1002/cnr2.70206","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>While there is a growing volume of evidence suggesting that relatively prevalent functional polymorphisms present within apoptosis-related genes may influence human prostate cancer (PCa) susceptibility, the clinical relevance of these findings remains inconclusive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This meta-analysis was thus developed with the goal of generating more precise estimates of the relationships between polymorphisms in four apoptosis-associated genes (NKX3-1, caspase-3, caspase-9, and BCL-2) and the risk of PCa.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The PubMed, Web of Science, Google Scholar, Embase, Cochrane Library, and SinoMed (CNKI and Wanfang) databases were searched for relevant studies published through December 20, 2023, using the following keywords: “polymorphism” or “variant” and “carcinoma” or “cancer” or “tumor” and “NKX3-1,” “CASP3” or “Caspase-3,” “CASP9” or “Caspase-9,” “BCL-2” or “B-cell lymphoma” and “prostate cancer” or “PCa” or “prostate adenocarcinoma.” This approach led to the identification of 22 case–control studies related to the association between apoptosis-related gene polymorphisms and PCa susceptibility enrolling 9706 cases and 12 567 controls. Subsequent analyses revealed that the <i>NKX3-1</i> rs2228013, <i>CASP9</i> rs1052571, and <i>CASP9</i> rs4645982 polymorphisms were associated with greater PCa risk, whereas the <i>CASP3</i> rs4647603 polymorphism was associated with a risk reduction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>These findings provide strong evidence for the potential contributions of polymorphisms in the apoptosis-related caspase-3, caspase-9, and NKX3-1 genes in the onset and progression of PCa.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70206","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAMDC2-AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma","authors":"Yifei Chen,&nbsp;Jun Liu,&nbsp;Ying Zhu","doi":"10.1002/cnr2.70216","DOIUrl":"https://doi.org/10.1002/cnr2.70216","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Multiple myeloma is a malignant disorder involving the uncontrolled proliferation of plasma cells in the bone marrow. Prognosis remains poor for individuals with relapsed and refractory multiple myeloma (RRMM), and the underlying mechanisms are yet to be fully understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We collected bone marrow RNA-Seq data from a total of 557 patients with MM from the GEO database (GSE24080) for further analysis, dividing them into relapsed/refractory and control groups. Additionally, we collected bone marrow samples from 57 MM patients to validate the performed RNA-Seq data analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RNA-Seq analysis of patients with RRMM revealed a significant upregulation of genes associated with cuproptosis. Using the LASSO Cox regression method, several long noncoding RNAs (lncRNAs) were identified that influence copper-induced cell death. Based on these lncRNAs, patients were stratified into high-risk and low-risk groups. The high-risk group exhibited a significantly worse overall survival (OS) compared to the low-risk group, with a <i>p</i>-value of less than 0.001. Our statistical analysis, incorporating LASSO Cox regression, indicated that among these lncRNAs, MAMDC2-AS1 was particularly noteworthy due to its strong correlation with OS (<i>p</i>-value &lt; 0.01). Further validation using qPCR and survival analysis established MAMDC2-AS1 as a strong predictor of prognosis in MM. This finding suggests that MAMDC2-AS1 can serve as a potential independent biomarker for RRMM. The qPCR data validated the RNA-Seq findings and uncovered the significance of MAMDC2-AS1 in the prognosis of this disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MAMDC2-AS1 plays a significant role in RRMM. Promisingly, Bortezomib, Bosutinib, Crizotinib, and DMOG have demonstrated promising efficacy in addressing advanced cases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Nomogram for Lung Adenocarcinoma Patients With Bone Metastasis Based on the SEER Database and an External Validation Cohort","authors":"Zhiming Liu,&nbsp;Min Zhang,&nbsp;Shuo Han,&nbsp;Hao Zhang,&nbsp;Shengwei Meng,&nbsp;Zhubin Shen,&nbsp;Xuexiao Ma","doi":"10.1002/cnr2.70211","DOIUrl":"https://doi.org/10.1002/cnr2.70211","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lung adenocarcinoma is a common type of cancer that can lead to bone metastasis and has a poor prognosis. Although previous studies have established nomograms for lung adenocarcinoma, these nomograms do not effectively predict the prognosis of lung adenocarcinoma patients with bone metastasis. This study aims to establish and validate a new nomogram to solve this problem.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were collected from the SEER database and from patients at our hospital who had been diagnosed with lung adenocarcinoma and developed bone metastases. The patients were randomly assigned into the training and internal validation sets in a 7:3 ratio. External validation was conducted using an independent patient cohort from two hospitals. Different methods were used to evaluate the nomogram's performance. The relationship between different metastatic sites and radiotherapy and chemotherapy was also analyzed to evaluate patient prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The following factors were identified as significant prognostic indicators: age, sex, marital status, T stage, N stage, tumor grade, tumor size, presence of brain and liver metastases, and receipt of chemotherapy. The nomogram's concordance indices for predicting overall survival were consistently above 0.7, and the area under the curve values, calibration plots, and decision curves all confirmed the nomogram's strong predictive accuracy. Moreover, our analysis revealed that chemotherapy was the most effective treatment modality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study developed a nomogram that can predict the prognosis of lung adenocarcinoma patients with bone metastasis. The results showed that patients with liver metastasis had the worst prognosis and that chemotherapy was the most effective treatment regimen for patients with different metastatic sites.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70211","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}